BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

521 related articles for article (PubMed ID: 30334995)

  • 1. Liquid biopsy prediction of axillary lymph node metastasis, cancer recurrence, and patient survival in breast cancer: A meta-analysis.
    Lee JH; Jeong H; Choi JW; Oh HE; Kim YS
    Medicine (Baltimore); 2018 Oct; 97(42):e12862. PubMed ID: 30334995
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Outcomes of locally advanced breast cancer patients with ≥ 10 positive axillary lymph nodes.
    Koca E; Kuzan TY; Dizdar O; Babacan T; Sahin I; Ararat E; Altundag K
    Med Oncol; 2013; 30(3):615. PubMed ID: 23729267
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mutation profiling in the PIK3CA, TP53, and CDKN2A genes in circulating free DNA and impalpable breast lesions.
    Delmonico L; Costa MASM; Fournier MV; Romano SO; Nascimento CMD; Barbosa AS; Moreira ADS; Scherrer LR; Ornellas MHF; Alves G
    Ann Diagn Pathol; 2019 Apr; 39():30-35. PubMed ID: 30634138
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Circulating Tumor DNA Is a Variant of Liquid Biopsy with Predictive and Prognostic Clinical Value in Breast Cancer Patients.
    Zavarykina TM; Lomskova PK; Pronina IV; Khokhlova SV; Stenina MB; Sukhikh GT
    Int J Mol Sci; 2023 Dec; 24(23):. PubMed ID: 38069396
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Association of Circulating Tumor DNA With Disease-Free Survival in Breast Cancer: A Systematic Review and Meta-analysis.
    Cullinane C; Fleming C; O'Leary DP; Hassan F; Kelly L; O'Sullivan MJ; Corrigan MA; Redmond HP
    JAMA Netw Open; 2020 Nov; 3(11):e2026921. PubMed ID: 33211112
    [TBL] [Abstract][Full Text] [Related]  

  • 6. High mutation burden of circulating cell-free DNA in early-stage breast cancer patients is associated with a poor relapse-free survival.
    Kujala J; Hartikainen JM; Tengström M; Sironen R; Kosma VM; Mannermaa A
    Cancer Med; 2020 Aug; 9(16):5922-5931. PubMed ID: 32602248
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical significance of gene mutation in ctDNA analysis for hormone receptor-positive metastatic breast cancer.
    Shibayama T; Low SK; Ono M; Kobayashi T; Kobayashi K; Fukada I; Ito Y; Ueno T; Ohno S; Nakamura Y; Takahashi S
    Breast Cancer Res Treat; 2020 Apr; 180(2):331-341. PubMed ID: 32020432
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Aberrant expression of δ-like ligand 4 contributes significantly to axillary lymph node metastasis and predicts postoperative outcome in breast cancer.
    Xiao M; Yang S; Ning X; Huang Y
    Hum Pathol; 2014 Nov; 45(11):2302-10. PubMed ID: 25260720
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Internal mammary nodal chain drainage is a prognostic indicator in axillary node-positive breast cancer.
    Yao MS; Kurland BF; Smith AH; Schubert EK; Dunnwald LK; Byrd DR; Mankoff DA
    Ann Surg Oncol; 2007 Oct; 14(10):2985-93. PubMed ID: 17564747
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Correlation Between Raf/MEK/ERK Signaling Pathway and Clinicopathological Features and Prognosis for Patients With Breast Cancer Having Axillary Lymph Node Metastasis.
    Shao GL; Wang MC; Fan XL; Zhong L; Ji SF; Sang G; Wang S
    Technol Cancer Res Treat; 2018 Jan; 17():1533034617754024. PubMed ID: 29529946
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Liquid biopsy in breast cancer: A comprehensive review.
    Alimirzaie S; Bagherzadeh M; Akbari MR
    Clin Genet; 2019 Jun; 95(6):643-660. PubMed ID: 30671931
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Circulating tumor DNA for predicting recurrence in patients with operable breast cancer: a systematic review and meta-analysis.
    Nader-Marta G; Monteforte M; Agostinetto E; Cinquini M; Martins-Branco D; Langouo M; Llombart-Cusac A; Cortés J; Ignatiadis M; Torri V; Apolone G; Cappelletti V; Pruneri G; de Azambuja E; Di Cosimo S
    ESMO Open; 2024 Mar; 9(3):102390. PubMed ID: 38460249
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Breast cancer prognosis and occult lymph node metastases, isolated tumor cells, and micrometastases.
    de Boer M; van Dijck JA; Bult P; Borm GF; Tjan-Heijnen VC
    J Natl Cancer Inst; 2010 Mar; 102(6):410-25. PubMed ID: 20190185
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Monitoring levels of circulating cell-free DNA in patients with metastatic colorectal cancer as a potential biomarker of responses to regorafenib treatment.
    Pastor B; André T; Henriques J; Trouilloud I; Tournigand C; Jary M; Mazard T; Louvet C; Azan S; Bauer A; Roch B; Sanchez C; Vernerey D; Thierry AR; Adenis A
    Mol Oncol; 2021 Sep; 15(9):2401-2411. PubMed ID: 33934494
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Optimal treatment of the axilla after positive sentinel lymph node biopsy in early invasive breast cancer. Early results of the OTOASOR trial].
    Sávolt A; Musonda P; Mátrai Z; Polgár C; Rényi-Vámos F; Rubovszky G; Kovács E; Sinkovics I; Udvarhelyi N; Török K; Kásler M; Péley G
    Orv Hetil; 2013 Dec; 154(49):1934-42. PubMed ID: 24292111
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact of axillary lymph node dissection on breast cancer outcome in clinically node negative patients: a systematic review and meta-analysis.
    Sanghani M; Balk EM; Cady B
    Cancer; 2009 Apr; 115(8):1613-20. PubMed ID: 19199349
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The prognostic value of circulating cell-free DNA in breast cancer: A meta-analysis.
    Tan G; Chu C; Gui X; Li J; Chen Q
    Medicine (Baltimore); 2018 Mar; 97(13):e0197. PubMed ID: 29595655
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The prevalence of estrogen receptor-1 mutation in advanced breast cancer: The estrogen receptor one study (EROS1).
    Najim O; Huizing M; Papadimitriou K; Trinh XB; Pauwels P; Goethals S; Zwaenepoel K; Peterson K; Weyler J; Altintas S; van Dam P; Tjalma W
    Cancer Treat Res Commun; 2019; 19():100123. PubMed ID: 30826563
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical significance of plasma cell-free DNA mutations in PIK3CA, AKT1, and ESR1 gene according to treatment lines in ER-positive breast cancer.
    Takeshita T; Yamamoto Y; Yamamoto-Ibusuki M; Tomiguchi M; Sueta A; Murakami K; Iwase H
    Mol Cancer; 2018 Feb; 17(1):67. PubMed ID: 29482551
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Accuracy of analysis of cfDNA for detection of single nucleotide variants and copy number variants in breast cancer.
    Yang X; Zhang K; Zhang C; Peng R; Sun C
    BMC Cancer; 2019 May; 19(1):465. PubMed ID: 31101027
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 27.